Acute Oxaliplatin‐induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical colorectal cancer

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clcc.2016.11.005PMID 27989485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug‐induced thrombotic microangiopathy: Experience of the Oklahoma registry and the BloodCenter of Wisconsin

  2015cited by this paper
• Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer.

  2015cited by this paper
• MANAGEMENT OF METASTATIC COLORECTAL CANCER: Current Treatments and New Therapies.

  2015cited by this paper
• Oxaliplatin-induced immune-mediated cytopenias: A case report and literature review

  2015cited by this paper
• Disseminated intravascular coagulation and immune hemolytic anemia, possibly Evans syndrome, after oxaliplatin and bevacizumab infusion for metastatic colon adenocarcinoma: a case report and literature review.

  2015cited by this paper
• Acute Immune Hematological Complication of Oxaliplatin. A Series of 3 Cases

  2014cited by this paper
• Oxaliplatin-Induced Renal Tubular Vacuolization

  2014cited by this paper
• Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.

  2014cited by this paper
• Oxaliplatin induced disseminated intravascular coagulation: A case report and review of literature.

  2012cited by this paper
• A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

  2012cited by this paper
• Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report.

  2011cited by this paper
• [Recurrent autoimmune hemolytic anemia induced by XELOX chemotherapy for colon cancer].

  2011cited by this paper
• Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review

  2010cited by this paper
• Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.

  2010cited by this paper
• Acute renal failure related to oxaliplatin-induced intravascular hemolysis

  2010cited by this paper
• Drug-induced immune hemolytic anemia

  2009cited by this paper
• Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review

  2009cited by this paper
• Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug‐induced nonimmunologic protein adsorption

  2009cited by this paper
• Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience

  2008cited by this paper
• Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report.

  2007cited by this paper
• Autoimmunhämolytische Anämie unter Oxaliplatin

  2007cited by this paper
• Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.

  2007cited by this paper
• Hemolytic uremic syndrome following the infusion of oxaliplatin: case report

  2006cited by this paper
• Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature.

  2005cited by this paper
• Oxaliplatin‐induced immune pancytopenia

  2005cited by this paper
• Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient

  2004cited by this paper
• Oxaliplatin-Induced Acute-Onset Thrombocytopenia, Hemorrhage and Hemolysis

  2004cited by this paper
• An immediate hemolytic reaction induced by repeated administration of oxaliplatin

  2004cited by this paper
• Oxaliplatin-safety profile: neurotoxicity.

  2003cited by this paper
• Oxaliplatin-related side effects: characteristics and management.

  2002cited by this paper
• Oxaliplatin-induced Evan's syndrome

  2001cited by this paper
• Immunohemolytic anemia following oxaliplatin administration.

  2000cited by this paper
• Oxaliplatin-induced haemolytic anaemia.

  1999cited by this paper
• Drug‐induced immune hemolytic anemia

  1992cited by this paper

• Successful Treatment of Oxaliplatin‐Induced Immune Thrombocytopenia in a Schizophrenic Patient With Contraindication to Steroids Using Cyclosporine Plus Eltrombopag: A Case Report

  2026cites this paper
• The Nephrotoxicity of Drugs Used in Causal Oncological Therapies

  2022cites this paper
• Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study

  2021cites this paper
• Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis

  2021cites this paper
• Serologic characteristics of oxaliplatin antibodies in 15 patients with drug‐induced immune hemolytic anemia

  2021cites this paper
• Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism.

  2019cites this paper
• Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.

  2018cites this paper